Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB0139 in Idiopathic Pulmonary Fibrosis
NCT03832946Phase 2Completed
- Sponsor
- Galecto, Inc.
- Start
- Feb 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing GB0139 3 mg with Placebo (2 arms). Primary endpoint: Annual Rate of Decline in Forced Vital Capacity (FVC) at 52 weeks. Started Feb 2019; status: completed.
02
Drugs
GB0139
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03832946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832946.